A report released today by Zacks Investment Research about Lantheus Holdings Inc (NASDAQ:LNTH) bumps the target price to $9.00
- Updated: October 15, 2016
Having a price of $8.02, Lantheus Holdings Inc (NASDAQ:LNTH) traded -3.51% lower on the day. With the last close up 65.14% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. LNTH has recorded a 50-day moving average of $8.49 and a 200-day moving average of $4.66. 367,435 shares of Lantheus Holdings Inc exchanged hands, down from an avg. volume of 463,248
Zacks Investment Research raised the target price of Lantheus Holdings Inc (NASDAQ:LNTH) to $9.00 indicating a possible upside of 0.12%.
With a market cap of $0, Lantheus Holdings Inc has 52 week low of $1.76 and a 52 week high of $10.10 with a PE ratio of 8.69 .
More About Lantheus Holdings Inc (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company's portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company's Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company's imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.